AIM ImmunoTech(US:AIM) Globenewswire·2026-02-23 13:55Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].